stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) EV/Sales
As of 5 November 2026, GSK PLC Sponsored ADR (GSK) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from 1.6× (September 2022) to 4.0× (December 2019); the current reading is higher than 62% of that period. That is below the Drug Manufacturers General industry median of 4.1× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.7× | 28.45% |
| FY2024 | 2.1× | (12.33%) |
| FY2023 | 2.4× | 1.43% |
| FY2022 | 2.4× | (18.06%) |
| FY2021 | 2.9× | 8.60% |
| FY2020 | 2.7× | (21.77%) |
| FY2019 | 3.4× | 15.15% |
| FY2018 | 3.0× | 8.71% |
| FY2017 | 2.8× | (8.32%) |
| FY2016 | 3.0× | 16.72% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.8× | (1.81%) |
| Jun 2026 | 2.8× | (6.28%) |
| Mar 2026 | 3.0× | 9.70% |
| Dec 2025 | 2.7× | 8.30% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNY Sanofi compare | 2.1× |
| GSK GSK PLC Sponsored ADR | 2.9× |
| BMY Bristol Myers Squibb Company compare | 3.2× |
| PFE Pfizer Inc. compare | 3.4× |
| NVO Novo Nordisk A/S compare | 3.8× |
| BIIB Biogen Inc. compare | 4.1× |
| AZN AstraZeneca PLC compare | 5.0× |
| GILD Gilead Sciences, Inc. compare | 7.4× |
| AMGN Amgen Inc. compare | 7.5× |
| Drug Manufacturers General industry median | 4.1× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement